Drug intelligence / Profile preview

XEN1120

Development stage: Unknown
Lead developer: Xenon Pharmaceuticals
Modality: Small Molecules
Administration: Oral (based On Typical Administration Route For Similar Kv7 Openers And Early Phase Studies)

Overview

XEN1120 is a novel small molecule analgesic developed by Xenon Pharmaceuticals. It acts as a Kv7 (KCNQ) potassium channel opener, specifically stimulating the KCNQ2 potassium channel. The drug is being investigated primarily for the treatment of pain and may have utility in other indications related to neuronal hyperexcitability. As of May 2025, it is classified as a new molecular entity and has reached Phase I clinical trials for pain[1][2][3].

Targets

KCNQ2 (Potassium voltage-gated channel subfamily KQT member 2)

Beyond the preview

Go deeper on XEN1120.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XEN1120.

Explore the full profile